{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T17:03:41Z","timestamp":1773421421784,"version":"3.50.1"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006559","name":"University of Tsukuba","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006559","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Several studies have suggested that naldemedine may reduce opioid-induced constipation (OIC) as well as opioid-induced nausea and vomiting (OINV). This study aimed to investigate prophylactic effects of naldemedine on OINV in patients initiating regular, oral, strong opioids for cancer pain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this preplanned secondary analysis of a multicenter, double-blind, randomized, placebo-controlled trial investigating the preventive effects of naldemedine on OIC, eligible patients were randomized in a 1:1 ratio to receive either naldemedine 0.2\u2009mg or placebo once daily for 14\u2009days. The primary endpoint was the complete response (CR) rate, defined as the proportion of patients with no vomiting episodes and no use of rescue antiemetics within the first three days of opioid initiation. The secondary endpoint was the nausea and vomiting score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 15 Palliative Care (EORTC QLQ-C15-PAL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 103 patients, 48 and 47 patients in each group started protocol treatment, respectively. The CR rate was significantly higher in the naldemedine group than in the placebo group (81.3% vs 38.3%, P\u2009&amp;lt;\u2009.001). Nausea and vomiting scores on the QLQ-C15-PAL at weeks 1 and 2 were significantly better in the naldemedine group (means 7.1 and 6.4) versus placebo (means 44.6 and 35.3; both P &amp;lt; .001). Within the total effect of naldemedine on the QLQ-C15-PAL nausea and vomiting scores at week 2, the proportion mediated through OIC reduction was 21.9%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Naldemedine may have intrinsic antiemetic potency to prevent both OIC and OINV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>https:\/\/jrct.niph.go.jp\/ (Japan Registry of Clinical Trials) Identifier: jRCTs031200397<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag047","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T12:28:09Z","timestamp":1771331289000},"source":"Crossref","is-referenced-by-count":0,"title":["Novel antiemetic effect of naldemedine in patients initiating opioids for cancer pain: a secondary analysis of a randomized clinical trial"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1024-1946","authenticated-orcid":false,"given":"Takahiro","family":"Higashibata","sequence":"first","affiliation":[{"name":"Department of Palliative and Supportive Care, Institute of Medicine, University of Tsukuba , Tsukuba 305-8575,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaomi","family":"Kessoku","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine , Yokohama 236-0004,","place":["Japan"]},{"name":"Department of Gastroenterology, International University Health and Welfare Graduate School of Medicine , Narita 286-8686,","place":["Japan"]},{"name":"Department of Palliative Medicine and Gastroenterology, International University Health and Welfare Narita Hospital , Narita 286-8520,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Kajiura","sequence":"additional","affiliation":[{"name":"Medical Oncology and Palliative Medicine Department, Toyama University Hospital , Toyama 930-0194,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mami","family":"Hirakawa","sequence":"additional","affiliation":[{"name":"Department of Palliative Medicine, St. Marianna University School of Medicine , Kawasaki 216-8511,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Oyamada","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Japanese Organisation for Research and Treatment of Cancer (JORTC) Data Center , Tokyo 116-0013,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Ariyoshi","sequence":"additional","affiliation":[{"name":"Department of Data Management, JORTC Data Center , Tokyo 116-0013,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Yamada","sequence":"additional","affiliation":[{"name":"Tsukuba Clinical Research & Development Organization (T-CReDO), University of Tsukuba , Tsukuba 305-8576,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Institute of Medicine, University of Tsukuba , Tsukuba 305-8575,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshikazu","family":"Moriwaki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Kurashiki Central Hospital , Kurashiki 710-8602,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroka","family":"Nagaoka","sequence":"additional","affiliation":[{"name":"Department of Palliative Care, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital , Tokyo 113-8677,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyuki","family":"Takashima","sequence":"additional","affiliation":[{"name":"Tsukuba Clinical Research & Development Organization (T-CReDO), University of Tsukuba , Tsukuba 305-8576,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Doki","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Institute of Medicine, University of Tsukuba , Tsukuba 305-8575,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan J","family":"Mathis","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Institute of Medicine, University of Tsukuba , Tsukuba 305-8575,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine , Yokohama 236-0004,","place":["Japan"]},{"name":"Department of Gastroenterology, International University Health and Welfare Graduate School of Medicine , Narita 286-8686,","place":["Japan"]},{"name":"Department of Palliative Medicine and Gastroenterology, International University Health and Welfare Narita Hospital , Narita 286-8520,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Fuyuki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine , Yokohama 236-0004,","place":["Japan"]},{"name":"Department of Palliative Care, Shinyurigaoka General Hospital , Kawasaki 215-0026,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine , Yokohama 236-0004,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yo","family":"Ishihara","sequence":"additional","affiliation":[{"name":"Department of Palliative Medicine and Gastroenterology, International University Health and Welfare Narita Hospital , Narita 286-8520,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuji","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Medical Oncology and Palliative Medicine Department, Toyama University Hospital , Toyama 930-0194,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Ando","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, Faculty of Medicine, Academic Assembly, University of Toyama , Toyama 930-0194,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, St. Marianna University Hospital , Kawasaki 216-8511,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Izawa","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, St. Marianna University School of Medicine , Kawasaki 216-8511,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiki","family":"Horie","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, St. Marianna University School of Medicine , Kawasaki 216-8511,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Morita","sequence":"additional","affiliation":[{"name":"Department of Palliative and Supportive Care, Seirei Mikatahara General Hospital , Hamamatsu 433-8558,","place":["Japan"]},{"name":"Research Association for Community Health , Hamamatsu 434-0046,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0304-9881","authenticated-orcid":false,"given":"Jun","family":"Hamano","sequence":"additional","affiliation":[{"name":"Department of Palliative and Supportive Care, Institute of Medicine, University of Tsukuba , Tsukuba 305-8575,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"2026031311565610200_oyag047-B1","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1200\/JCO.22.02198","article-title":"Use of opioids for adults with pain from cancer or cancer treatment: ASCO Guideline","volume":"41","author":"Paice","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026031311565610200_oyag047-B2","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1200\/JCO.2001.19.9.2542","article-title":"Strategies to manage the adverse effects of oral morphine: an evidence-based report","volume":"19","author":"Cherny","year":"2001","journal-title":"J Clin Oncol"},{"key":"2026031311565610200_oyag047-B3","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1016\/S1470-2045(12)70040-2","article-title":"Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC","volume":"13","author":"Caraceni","year":"2012","journal-title":"Lancet Oncol"},{"key":"2026031311565610200_oyag047-B4","doi-asserted-by":"publisher","first-page":"iv166","DOI":"10.1093\/annonc\/mdy152","article-title":"Management of cancer pain in adult patients: ESMO clinical practice guidelines","volume":"29","author":"Fallon","year":"2018","journal-title":"Ann Oncol"},{"key":"2026031311565610200_oyag047-B5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ejphar.2013.09.074","article-title":"Opioid induced nausea and vomiting","volume":"722","author":"Smith","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"2026031311565610200_oyag047-B6","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/0885-3924(91)90041-2","article-title":"The incidence of narcotic-induced emesis","volume":"6","author":"Campora","year":"1991","journal-title":"J Pain Symptom Manage"},{"key":"2026031311565610200_oyag047-B7","doi-asserted-by":"publisher","first-page":"CD011056","DOI":"10.1002\/14651858.CD011056.pub2","article-title":"Impact of morphine, fentanyl, oxycodone or codeine on patient consciousness, appetite and thirst when used to treat cancer pain","volume":"2014","author":"Wiffen","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2026031311565610200_oyag047-B8","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.ejpain.2008.09.005","article-title":"Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine","volume":"13","author":"Wirz","year":"2009","journal-title":"Eur J Pain"},{"key":"2026031311565610200_oyag047-B9","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/s00520-019-04884-0","article-title":"A preliminary study of the effect of naldemedine tosylate on opioid-induced nausea and vomiting","volume":"28","author":"Sato","year":"2020","journal-title":"Support Care Cancer"},{"key":"2026031311565610200_oyag047-B10","doi-asserted-by":"publisher","first-page":"118048","DOI":"10.1016\/j.lfs.2020.118048","article-title":"Preventive effects of naldemedine, peripherally acting \u03bc-opioid receptor antagonist, on morphine-induced nausea and vomiting in ferrets","volume":"257","author":"Kanemasa","year":"2020","journal-title":"Life Sci"},{"key":"2026031311565610200_oyag047-B11","doi-asserted-by":"publisher","first-page":"8097","DOI":"10.1007\/s00520-021-06437-w","article-title":"MASCC antiemetics in advanced cancer updated guideline","volume":"29","author":"Davis","year":"2021","journal-title":"Support Care Cancer"},{"key":"2026031311565610200_oyag047-B12","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1007\/s00520-024-08628-7","article-title":"Pharmacological treatment of cancer pain and opioid induced nausea and vomiting: online survey and comparison with current guidelines","volume":"32","author":"Gaertner","year":"2024","journal-title":"Support Care Cancer"},{"key":"2026031311565610200_oyag047-B13","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1634\/theoncologist.2017-0225","article-title":"Efficacy of prophylactic treatment for oxycodone-induced nausea and vomiting among patients with cancer pain (POINT): a randomized, placebo-controlled, double-blind trial","volume":"23","author":"Tsukuura","year":"2018","journal-title":"Oncologist"},{"key":"2026031311565610200_oyag047-B14","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s00520-001-0332-1","article-title":"A double-blind, randomised, parallel group, multinational, multicentre study comparing a single dose of ondansetron 24 mg p.o. with placebo and metoclopramide 10 mg t.d.s. p.o. in the treatment of opioid-induced nausea and emesis in cancer patients","volume":"10","author":"Hardy","year":"2002","journal-title":"Support Care Cancer"},{"key":"2026031311565610200_oyag047-B15","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1124\/jpet.119.264515","article-title":"Pharmacological profile of naldemedine, a peripherally acting \u03bc-opioid receptor antagonist: comparison with naloxone and naloxegol","volume":"373","author":"Kanemasa","year":"2020","journal-title":"J Pharmacol Exp Ther"},{"key":"2026031311565610200_oyag047-B16","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.lfs.2018.07.028","article-title":"Pharmacological profile of TAN-452, a novel peripherally acting opioid receptor antagonist for the treatment of opioid-induced bowel syndromes","volume":"215","author":"Suzuki","year":"2018","journal-title":"Life Sci"},{"key":"2026031311565610200_oyag047-B17","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.3390\/cancers14092112","article-title":"Effectiveness of naldemedine compared with magnesium oxide in preventing opioid-induced constipation: a randomized controlled trial","volume":"14","author":"Ozaki","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026031311565610200_oyag047-B18","doi-asserted-by":"publisher","first-page":"4206","DOI":"10.1200\/JCO.24.00381","article-title":"Naldemedine for opioid-induced constipation in patients with cancer: a multicenter, double-blind, randomized, placebo-controlled trial","volume":"42","author":"Hamano","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026031311565610200_oyag047-B19","doi-asserted-by":"publisher","first-page":"100967","DOI":"10.1016\/j.conctc.2022.100967","article-title":"Rationale and design of a multicenter, double-blinded, randomized, placebo-controlled trial to investigate the effects of naldemedine on opioid-induced constipation for patients with cancer pain: a study protocol","volume":"29","author":"Higashibata","year":"2022","journal-title":"Contemp Clin Trials Commun"},{"key":"2026031311565610200_oyag047-B20","doi-asserted-by":"publisher","first-page":"c332","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ"},{"key":"2026031311565610200_oyag047-B21","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1001\/jama.2021.14075","article-title":"A guideline for reporting mediation analyses of randomized trials and observational studies: the AGReMA statement","volume":"326","author":"Lee","year":"2021","journal-title":"JAMA"},{"key":"2026031311565610200_oyag047-B22","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1093\/annonc\/mdp195","article-title":"A phase II study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy","volume":"20","author":"Maemondo","year":"2009","journal-title":"Ann Oncol"},{"key":"2026031311565610200_oyag047-B23","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ejca.2005.06.022","article-title":"The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care","volume":"42","author":"Groenvold","year":"2006","journal-title":"Eur J Cancer"},{"key":"2026031311565610200_oyag047-B24","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s11136-011-9939-y","article-title":"Verification of the psychometric properties of the Japanese version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 15 palliative (EORTCQLQ-C15-PAL)","volume":"21","author":"Miyazaki","year":"2012","journal-title":"Qual Life Res"},{"key":"2026031311565610200_oyag047-B25","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1007\/s11136-016-1308-4","article-title":"Minimal clinically important differences in the EORTC QLQ-BM22 and EORTC QLQ-C15-PAL modules in patients with bone metastases undergoing palliative radiotherapy","volume":"25","author":"Raman","year":"2016","journal-title":"Qual Life Res"},{"key":"2026031311565610200_oyag047-B26","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3111\/13696990903430481","article-title":"Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation","volume":"12","author":"Rentz","year":"2009","journal-title":"J Med Econ"},{"key":"2026031311565610200_oyag047-B27","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1177\/147323001103900106","article-title":"The Bowel Function Index for evaluating constipation in pain patients\u202f: definition of a reference range for a non-constipated population of pain patients","volume":"39","author":"Ueberall","year":"2011","journal-title":"J Int Med Res"},{"key":"2026031311565610200_oyag047-B28","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1080\/15360288.2020.1829250","article-title":"Predictive factors of opioid-induced nausea in cancer patients","volume":"35","author":"Ogawa","year":"2021","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"2026031311565610200_oyag047-B29","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1089\/jpm.2013.0613","article-title":"Predictive factors for nausea or vomiting in patients with cancer who receive oral oxycodone for the first time: is prophylactic medication for prevention of opioid-induced nausea or vomiting necessary?","volume":"17","author":"Kanbayashi","year":"2014","journal-title":"J Palliat Med"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag047\/66981775\/oyag047.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/4\/oyag047\/66981775\/oyag047.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/4\/oyag047\/66981775\/oyag047.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T15:57:04Z","timestamp":1773417424000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag047\/8489916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,3,9]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag047","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,2,18]]},"article-number":"oyag047"}}